Literature DB >> 21573252

Lupus, the current therapeutic approaches.

M Wong1, A La Cava.   

Abstract

The management of systemic lupus erythematosus (SLE) is challenging due to the heterogenous presentation and clinical manifestations of the disease. Standard therapies for SLE use immunosuppressive drugs with significant side effects. Advanced knowledge of the pathogenesis of SLE has led to new therapeutic approaches targeting specific molecules, pathways and cells. Factors intimately involved in the chronic inflammatory response to SLE have been studied in animal models of the disease and tested in clinical trials. Here we review the topic discussing the agents currently used in the induction and maintenance therapy of SLE. In addition, the emerging therapeutic modalities in SLE that use biologics such as monoclonal antibodies to immune cell surface molecules or cytokines, synthetic peptides, oligonucleotides and cell-based therapies are discussed here. 2011 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21573252     DOI: 10.1358/dot.2011.47.4.1583186

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  3 in total

1.  Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.

Authors:  David A Horwitz; Sean Bickerton; Michael Koss; Tarek M Fahmy; Antonio La Cava
Journal:  Arthritis Rheumatol       Date:  2019-03-05       Impact factor: 10.995

Review 2.  Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.

Authors:  Eben I Lichtman; Simon M Helfgott; Martin A Kriegel
Journal:  Clin Immunol       Date:  2012-04-06       Impact factor: 3.969

3.  Leptin enhances availability of apoptotic cell-derived self-antigen in systemic lupus erythematosus.

Authors:  Gil Amarilyo; Noriko Iikuni; Aijing Liu; Giuseppe Matarese; Antonio La Cava
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.